ATE428425T1 - Spla2-inhibitoren zur behandlung von arteriosklerose - Google Patents

Spla2-inhibitoren zur behandlung von arteriosklerose

Info

Publication number
ATE428425T1
ATE428425T1 AT02705327T AT02705327T ATE428425T1 AT E428425 T1 ATE428425 T1 AT E428425T1 AT 02705327 T AT02705327 T AT 02705327T AT 02705327 T AT02705327 T AT 02705327T AT E428425 T1 ATE428425 T1 AT E428425T1
Authority
AT
Austria
Prior art keywords
arteriosclerosis
treatment
spla2 inhibitors
treating
group
Prior art date
Application number
AT02705327T
Other languages
German (de)
English (en)
Inventor
Akihiko Saiga
Takashi Ono
Katsutoshi Yamada
Kohji Hanasaki
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of ATE428425T1 publication Critical patent/ATE428425T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02705327T 2001-03-19 2002-03-19 Spla2-inhibitoren zur behandlung von arteriosklerose ATE428425T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001078569 2001-03-19
JP2001401289 2001-12-28
PCT/JP2002/002585 WO2002074342A1 (en) 2001-03-19 2002-03-19 Remedies for arteriosclerosis

Publications (1)

Publication Number Publication Date
ATE428425T1 true ATE428425T1 (de) 2009-05-15

Family

ID=26611547

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02705327T ATE428425T1 (de) 2001-03-19 2002-03-19 Spla2-inhibitoren zur behandlung von arteriosklerose

Country Status (14)

Country Link
US (1) US20040248898A1 (OSRAM)
EP (2) EP1378246B1 (OSRAM)
JP (1) JP4499361B2 (OSRAM)
KR (1) KR100908968B1 (OSRAM)
CN (1) CN1553814B (OSRAM)
AT (1) ATE428425T1 (OSRAM)
BR (1) BR0208275A (OSRAM)
CA (1) CA2441110C (OSRAM)
DE (1) DE60231969D1 (OSRAM)
ES (1) ES2324766T3 (OSRAM)
MX (1) MXPA03008440A (OSRAM)
PT (1) PT1378246E (OSRAM)
TW (1) TWI314457B (OSRAM)
WO (1) WO2002074342A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000621A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
KR20070091607A (ko) 2004-10-12 2007-09-11 디코드 제네틱스, 아이엔씨. 폐쇄성 동맥 질환용의 설폰아미드 주변 치환된바이사이클릭 화합물
US8329913B2 (en) 2004-10-29 2012-12-11 Zeria Pharmaceutical Co., Ltd. Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
EP1948602A2 (en) * 2005-11-03 2008-07-30 Ilypsa, Inc. Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors
RU2008149518A (ru) 2006-05-16 2010-06-27 Декод Дженетикс, Ехф. (Is) Способ получения 7-(акрилоил) индолов
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
CN101742907A (zh) * 2007-05-03 2010-06-16 安塞拉制药有限公司 采用分泌型磷脂酶a2（spla2）抑制剂和spla2抑制剂组合疗法治疗心血管疾病和血脂异常
US20090062369A1 (en) * 2007-08-31 2009-03-05 Joaquim Trias Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels
WO2010038104A1 (en) * 2008-10-03 2010-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event.
WO2010127099A2 (en) 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR101037404B1 (ko) * 2010-12-07 2011-05-30 박철형 가변설치가 가능한 압출본체에 의한 천장용 엘이디 조명등

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109309A (en) 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
JPH08500740A (ja) * 1993-06-25 1996-01-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー リポタンパク質関連ホスホリパーゼａ▲下２▼、その阻害剤および診断および治療におけるその使用
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
PT675110E (pt) 1994-04-01 2002-11-29 Lilly Co Eli 1h-indole-3-glioxilamidas inibidoras da spla2
US6214876B1 (en) * 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
BR9508298A (pt) 1994-07-21 1998-11-03 Shionogi & Co Inibidores de indolizina de spla2
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
BR9612347A (pt) 1995-12-13 1999-07-13 Lilly Co Eli Naftil acetamidas como inibidores de spla2
HUP9902120A3 (en) 1995-12-13 1999-12-28 Lilly Co Eli Naphthyl glyoxamides as spla2 inhibitors
CA2269203A1 (en) 1996-10-30 1998-05-07 Nicholas James Bach Substituted tricyclics
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US6407104B1 (en) * 1998-03-31 2002-06-18 Shionogi & Co., Ltd. Pyrrolo[1,2-a]pyrazine spla2 inhibitor
HUP0103546A3 (en) * 1998-05-21 2002-12-28 Shionogi & Co Pyrrolo[1,2-b]pyridazine derivatives having spla2 inhibitory effect and pharmaceutical compositions thereof
DE69931963D1 (de) * 1998-10-14 2006-07-27 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
US6756376B1 (en) * 1999-11-15 2004-06-29 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
WO2002000621A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect

Also Published As

Publication number Publication date
CA2441110C (en) 2010-10-12
EP1378246B1 (en) 2009-04-15
EP2044958A3 (en) 2009-07-08
EP2044958A2 (en) 2009-04-08
MXPA03008440A (es) 2004-01-29
KR100908968B1 (ko) 2009-07-22
EP1378246A4 (en) 2004-07-07
US20040248898A1 (en) 2004-12-09
JP4499361B2 (ja) 2010-07-07
CA2441110A1 (en) 2002-09-26
EP1378246A1 (en) 2004-01-07
PT1378246E (pt) 2009-05-22
WO2002074342A1 (en) 2002-09-26
TWI314457B (OSRAM) 2009-09-11
JPWO2002074342A1 (ja) 2004-07-08
ES2324766T3 (es) 2009-08-14
DE60231969D1 (de) 2009-05-28
CN1553814B (zh) 2010-05-26
KR20030085026A (ko) 2003-11-01
BR0208275A (pt) 2004-04-13
CN1553814A (zh) 2004-12-08

Similar Documents

Publication Publication Date Title
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE428425T1 (de) Spla2-inhibitoren zur behandlung von arteriosklerose
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE69738815D1 (de) Verwendung von Cyclooxygenase-2 Inhibitoren zur Behandlung und Vorbeugung von Neoplasia
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
ATE377010T1 (de) Caspase-inhibitoren und ihre verwendungen
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE313540T1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
ATE274521T1 (de) Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
DE60026279D1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
DE60317098D1 (de) Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE330938T1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties